Obesity drug pipeline & indications

Every disclosed cardiometabolic asset by sponsor and phase, and where each molecule is approved or in trials beyond weight loss - across the sponsors racing in obesity.

As of 2026-07-03. Updated as catalysts move.

Indications beyond weight loss #

Where each molecule is approved or in trials across the cardiometabolic franchise - the label-expansion thesis that drives the durable value. Indications attach to the molecule (e.g. semaglutide's cardiovascular win covers the whole franchise), so rows are molecules, not obesity SKUs. Click any cell to open the trial on ClinicalTrials.gov.

Molecule Obesity Type 2 diabetes CV outcomes MASH CKD / kidney OSA HFpEF
SemaglutideWegovy / Ozempic / Rybelsus Approved Approved Approved Approved Approved – Ph3
TirzepatideZepbound / Mounjaro Approved Approved Ph3 Ph3 – Approved Filed
CagriSema(cagrilintide + semaglutide) Filed Ph3 Ph3 – – – –
Retatrutide(GGG triple agonist) Ph3 Ph3 Ph3 Ph3 – – –
OrforglipronFoundayo (oral SMD) Approved Filed – – – – –
Survodutide(GLP-1/glucagon) Ph3 Ph3 – Ph3 – – –
MariTidemaridebart cafraglutide Ph3 Ph3 – – – – –
Eloralintide(amylin AMY1R) Ph3 Ph3 – – – Ph3 –
Petrelintide(amylin, Zealand/Roche) Ph2 – – – – – –

Approved / Filed / Phase 3 / Phase 2; – = not pursued. Cells link to the trial on ClinicalTrials.gov. As of 2026-06-25.

Pipelines #

Every disclosed cardiometabolic asset by sponsor and phase. Lilly does not disclose Phase 1 publicly.

Sponsor Filed Phase 3 Phase 2 Phase 1

Sector M&A and partnerships #

Deals that built the current obesity field. Most recent first.

2026-03
Eli Lilly → Centessa Pharmaceuticals plc.
$Acquisition
Asset: Multiple programs; cardiometabolic adjacency
Disclosed in Q1 2026 earnings; details limited.
2025-12
Eli Lilly → Orna Therapeutics
$Acquisition
Asset: circular RNA platform (not obesity-specific but tools the pipeline)
Platform play more than direct obesity asset.
2025-09
Pfizer → Metsera
$10B (largest obesity deal to date)
Asset: MET-097i / berobenatide-Ph3 ready, plus MET-233i (amylin), MET-034i (GIPR), MET-815i (quarterly GLP-1 prodrug)
Pfizer's return to obesity after internal danuglipron failure; entire Metsera obesity pipeline.
2025-06
Novo Nordisk → Akero Therapeutics
$5.9B equity
Asset: Efruxifermin (FGF21 analog for MASH)
Adjacency play: MASH overlap with obesity Wegovy ESSENCE expansion.
2025-03
Novo Nordisk → United Biotechnology (license, ex-China)
$200M upfront + milestones
Asset: UBT251 (GLP-1/GIP/glucagon triple agonist)
Novo's answer to Retatrutide. Ph2 China at 6 mg / 24 wk: -19.7% weight loss.
2024-12
Roche / Zealand Pharma → Petrelintide partnership
$1.65B upfront + 1.2B milestones
Asset: Petrelintide (long-acting amylin analog)
50/50 development and profit share; Phase 3 trigger payment to Zealand H2 2026 ($700M).
2024-08
Novo Nordisk → Inversago Pharma
$1.075B (incl. milestones)
Asset: Monlunabant (peripheral CB1 inverse agonist)
Non-incretin obesity mechanism; resurrects rimonabant concept with peripheral selectivity.
2023-12
Roche → Carmot Therapeutics
$2.7B upfront + 0.4B milestones
Asset: CT-388 (enicepatide, GLP-1/GIP dual), CT-996 (oral GLP-1), CT-868
Roche's entry into incretin obesity drugs.
2023-12
Eli Lilly → Versanis Bio
$1.92B upfront
Asset: Bimagrumab (anti-ActRII antibody for fat-selective weight loss)
Adds muscle-preserving mechanism to Lilly's obesity toolbox.